Operations: Xtep International Holdings Limited generates revenue from the design, development, manufacturing, and marketing of sports footwear, apparel, and accessories for both adults and children in China.

Dividend Yield: 4.3%

Xtep International Holdings has announced an interim dividend of HK$0.156 per share for H1 2024, up from HK$0.137 a year ago, with a special dividend of HK$0.447 per share also declared. Despite its dividends being well-covered by earnings (payout ratio: 45.1%) and cash flows (cash payout ratio: 35.5%), the company’s dividend history has been volatile over the past decade, making it less reliable for consistent income seekers despite recent growth in earnings and operational performance improvements.

• Click here and access our complete dividend analysis report to understand the dynamics of Xtep International Holdings.

• Insights from our recent valuation report point to the potential undervaluation of Xtep International Holdings shares in the market.

Consun Pharmaceutical Group

Simply Wall St Dividend Rating: ★★★★★☆

Overview: Consun Pharmaceutical Group Limited researches, develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People’s Republic of China with a market cap of HK$4.98 billion.

Operations: Consun Pharmaceutical Group Limited generates revenue from two primary segments: the Yulin Pharmaceutical Segment, which contributes CN￥395.06 million, and the Consun Pharmaceutical Segment, which brings in CN￥2.20 billion.

Dividend Yield: 9.9%

Consun Pharmaceutical Group announced an interim dividend of HK$0.3 per share for H1 2024, reflecting its commitment to shareholder returns despite a historically unstable dividend track record. The company's earnings and cash flows sufficiently cover the dividends, with payout ratios of 41.2% and 59.2% respectively. Recent earnings growth to CNY 399.77 million from CNY 347.89 million last year supports its current dividend yield, which is among the top in Hong Kong's market.

• Get an in-depth perspective on Consun Pharmaceutical Group's performance by reading our dividend report here.

• Upon reviewing our latest valuation report, Consun Pharmaceutical Group's share price might be too pessimistic.

Where To Now?

• Click through to start exploring the rest of the 82 Top SEHK Dividend Stocks now.

• Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.

• Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.

Searching for a Fresh Perspective?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.

• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include SEHK:1258 SEHK:1368 and SEHK:1681.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]